IGF1R and breast cancer: Promising experimental data have been provided using a dual IGF-1R/IR tyrosine kinase inhibitor, named BMS-536924, which showed the capability to prevent proliferative and migratory features of BC cells (Law et al., 2008; Litzenburger et al., 2009), without adverse effects associated with the insulin deficiency (Dool et al., 2011).